Refractory Medulloblastoma Suspended Phase 2 Trials for Ulixertinib (DB13930)

IndicationStatusPhase
DBCOND0105102 (Refractory Medulloblastoma)Suspended2
clinicaltrials.gov IdentifierTitlePurposeDrugs